The 19th Annual Koch Institute Summer Symposium will be held virtually on September 17, 2021 and will focus on cancer immunotherapy.
Cancer immunotherapy has revolutionized the landscape of cancer treatment, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy, culminating in multiple FDA-approved treatments and the awarding of the 2018 Nobel Prize in Medicine to Jim Allison and Tasuku Honjo, the field is currently at a critical juncture.
While checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer, the next generation of treatments will require us to understand what causes resistance in non-responders, how this can be overcome, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy.
Targeting T Cells
Rafi Ahmed, Michael Dougan, Chris Love
Thinking Beyond T Cells
Yasmine Belkaid, Stefani Spranger, Lauren Zasadil
Engineering Clinical Translation
Nina Bhardwaj, Chris Garcia, Crystal Mackall
Daniel Chen, Howard Kaufman, Kimberly Schaefer-Weaver
Moderator: Steven Silverstein
Agilent Technologies, Inc.
Dragonfly Therapeutics, Inc.
Repertoire Immune Medicines